New York City has a goal to become one of the premier biotech hubs in the US – on par with innovation centers like Cambridge, MA, and San Francisco. The city launched LifeSci NYC in 2016 with a $1bn public investment to create new jobs, foster talent and establish lab and incubator space, and it has made progress toward its goal of cultivating 1,000 R&D-stage companies and 40,000 new jobs in the city.
NYC’s Ambition: Be A Premier Biotech Hub
New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.
More from Financing
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
More from Business
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?